Search filters

List of works by Kanti Rai

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712

scientific article

Chronic lymphocytic leukaemia

article

Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options

scientific article published on 26 February 2019

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

scientific article

Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia

scientific article published on 14 March 2018

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

scientific article

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

scientific article published on 23 July 2015

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium

scientific article

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

scientific article published on March 2004

Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins

scientific article published on 15 April 2019

Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion

scientific article published on 01 August 2018

Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.

scientific article

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

scientific article

Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.

scientific article published on 09 May 2013

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

scientific article

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

scientific article published on 24 June 2008

Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium ⬇️

scientific article published on December 1, 2010

Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study ⬇️

scientific article published on December 1, 2010

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

scientific article

Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection

scientific article published on 7 March 2008

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

scientific article

Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

scientific article published on 02 June 2012

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

scientific article published in August 2004

Paulina is supported by:

About Paulina

Help